Kai Wucherpfennig

Has grant

Professor and Department Chair

Dana-Farber Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Strategy to Enhance Tumor Infiltration by Vaccine-induced T cells

Open Date: 2026-02-01

Close Date: 2028-01-31

Articles (17)

Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells

Year:

2025

Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.

Year:

2025

Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.

Year:

2025

Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.

Year:

2025

Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.

Year:

2025

Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.

Year:

2025

Supplementary Figure 3. Digital quantification from immunohistochemistry. Digital quantification from immunohistochemistry for T cell subsets and marker analysis from paired tumor samples for five patients enrolled to cohort A.

Year:

2025

Supplementary Figure 1. CODEX panel and experimental procedure. CODEX panel used to identify tumor cell subpopulations, immune cell populations and key cellular markers. (B) Experimental workflow for 5 pre- and post-treatment FFPE samples. ROIs were selected for multiplexed imaging and downstream analysis. (C) U Map clusters show major cell populations. Immune populations showed similar clustering in pre- and post- treatment samples.

Year:

2025

Supplementary Figure 6. Cell-cell interaction analyses. Cell-cell interaction comparison in pre- and post-treatment tumor samples using CODEX for patient #5. (A) All significant interacting cell types shown in the entire analyzed tumor region as annotated. (B) Example images of cell – cell interactions showing interaction of CD163+ macrophages with GZMB+ CD8 T cells, CD163+ macrophages with GZMB+ CD4 T cells, CD68+ macrophages with GZMB+ CD8 T cells. The plus sign indicates interactions that were in close proximity at a one-cell distance (20 pixels).

Year:

2025

Purpose: Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent glioblastoma. Patients and Methods: Sixty patients with recurrent glioblastoma received pembrolizumab with re-irradiation alone (cohort A, bevacizumab-naïve; n = 30) or with bevacizumab continuation (cohort B, n = 30). Dual primary endpoints, including the overall response rate and overall survival (OS) at either 12 (OS-12; cohort A) or 6 months (OS-6; cohort B), were assessed per cohort relative to historic benchmarks. Paired paraffin-embedded formalin-fixed tumor samples were assessed for immunologic biomarkers by IHC using digital quantification and co-detection-by-indexing (CODEX). Results: Study therapy was well tolerated, with most toxicities being grade ≤3. For cohort B, the primary endpoint of OS-6 was achieved (57%); however, survival was not improved for cohort A patients. The overall response rate was 3.3% and 6.7% for cohorts A and B, respectively. CODEX analysis of paired tumor samples from five patients revealed an increase of activated T cells in the tumor microenvironment after study therapy. Conclusions: Compared with historic controls, re-irradiation plus pembrolizumab seemed to improve survival among bevacizumab-refractory patients but not among bevacizumab-naïve patients. CODEX revealed evidence of intratumoral infiltration of activated immune effector cells. A randomized, properly controlled trial of PD-1 blockade plus re-irradiation is warranted to further evaluate this regimen for bevacizumab-refractory patients, but alternative approaches are needed for bevacizumab-naïve patients.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (26)

Daphne Haas-Kogan

Professor and Chair

Harvard University

UNITED STATES
View details

Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maxime Meylan

Dana-Farber Cancer Institute

UNITED STATES
View details

Mario Suva

Professor

Harvard Medical School

UNITED STATES
View details

Roni Wilke

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sanghoon Lee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tony J.C. Wang

Columbia University

UNITED STATES
View details

Yibo Dai

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gwyn Richardson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pamela Soliman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Keith Ligon

Chief of Neuropathology/Principal Investigator

Dana-Farber Cancer Institute

UNITED STATES
View details

Shyam Tanguturi

Vice Chair, Network Strategy & Business Development

Dana-Farber Cancer Institute

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Boruta

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yoshinaga Ito

Professor

Kyoto University

JAPAN
View details

Stephen J Bagley

University of Pennsylvania

UNITED STATES
View details